Raw Material Shortages – Midas is actively approaching these challenges

BfArM reports an increase in supply shortage notifications in the recent years (Source: German Government's comments on supply shortages, printed matter 19/13357; dossier on supply shortages of BfArM https://www.bfarm.de/EN):

• In the recent years China intensified its effective and overdue measures to improve the environmental situation. By shrinking the number of outdated production capacities and setting stricter emission limits and controls, especially capacities for raw materials based on critical chemistry are affected.
  
  • Currently, the National Blue Sky Action Plan 2018 – 2020 is in place, targeting among other the reduction of average density of fine particulate matter (PM2.5) by 15% (vs. 2015).  
  • The devastating explosion in Yancheng in China's eastern Jiangsu province in March 2019, caused a special action plan, incl. e.g. the target to decrease the number of chemical producers in Jiangsu from 5,433 to 2,000 by end of 2020 and down to max. 1,000 by 2022.
    
    
• UK frequently updates a list of drugs that cannot be parallel exported from the UK because they are needed for UK patients.
• Temporary closures of manufacturing sites due to Covid-19 pandemic and the related impact on the global logistics sector.
• On March 3rd 2020 India had executed an export ban of 26 APIs and formulations to secure the availability of these drugs in the domestic market. India has lifted the export ban partially in second week of April.